Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ejiao Yangxue Granules is a Traditional Chinese Medicine (TCM) product developed and manufactured by Anqing Echo Biopharmaceutical. It is primarily indicated for the treatment of Qi and blood deficiency, a condition in TCM characterized by symptoms such as dizziness, palpitations, loss of appetite, and anemia. The formulation is a combination of several herbal extracts, with Ejiao (Colla Corii Asini) serving as the primary active component known for its blood-enriching properties. Other ingredients typically include Rehmannia glutinosa, Codonopsis pilosula, and Astragalus membranaceus, which work synergistically to tonify blood and replenish vital energy (Qi). The product is approved in China and is administered orally in a granule formulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ejiao yangxue granules.